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Abstract 
Introduction: Variants in the GBA1 gene have been identified as a common risk factor for Parkinson’s 
disease (PD). In addition to pathogenic mutations (those associated with Gaucher disease), a number of 
“non-pathogenic” variants also occur at increased frequency in PD. Previous studies have reported that 
pathogenic variants adversely affect the clinical course of PD. The role of “non-pathogenic” GBA1 
variants on PD course is less clear. In this study we report the effect of GBA1 variants in incident PD 
patients with long-term follow up. 
Methods: The study population consisted of patients in the CamPaIGN and PICNICS cohorts. Patients 
were grouped into non-carriers, carriers of “non-pathogenic” GBA1 variants, and carriers of pathogenic 
GBA1 mutations. Survival analyses for time to development of dementia, postural instability and death 
were carried out. Cox-regression analysis controlling for potential confounders were used to determine 
the impact of GBA1 variants on these outcome measures. 
Results: GBA1 variants were identified in 14.4% of patients. Pathogenic and “non-pathogenic” GBA1 
variants were associated with the accelerated development of dementia and a more aggressive motor 
course. Pathogenic GBA1 variants were associated with earlier mortality in comparison to non-carriers, 
independent of the development of dementia. 
Discussion: GBA1 variants, including those not associated with Gaucher disease, are common in PD, 
and result in a more aggressive disease course. 
 
Introduction 
 
Heterozygous mutations in the GBA1 gene have been identified as a common risk factor for Parkinson’s 
disease (PD), being found in approximately 5 % of patients1-4. Biallelic pathogenic mutations result in 
the lysosomal storage disorder, Gaucher disease (GD)5. In addition to the known pathogenic mutations 
associated with GD, there are a number of “non-pathogenic” GBA1 variants that are not associated with 
GD, but that are found at increased frequency in PD patients, including the common E326K and T369M 
variants6-9. Carrying a pathogenic GBA1 mutation conveys an earlier age of onset10 11 and adversely 
affects the clinical course of PD, manifested by an increased risk of cognitive decline and dementia1 10 
12 13 14-18 and increased rate of motor progression1 10 12 19 20. However, some studies have found no effect 
on motor progression in GBA1 mutation-associated PD14 15 17. Few studies have commented on the effect 
of GBA1 mutations on mortality in PD, though some have suggested that survival time is reduced in 
GBA1 mutation carriers10 16. The clinical significance of carrying a “non-pathogenic” GBA1 variant is 
disputed14 21 though the E326K variant in particular has been associated with an adverse clinical course 
in PD in some studies20 22. 
 
We previously reported on the epidemiology of GBA1 mutation-associated PD in incident PD1. Here 
we present long-term follow-up data of incident PD cases carrying pathogenic and “non-pathogenic” 
variants in the GBA1 gene, from two community-based cohorts: the “Cambridgeshire Incidence of 
Parkinson’s disease from General Practice to Neurologist” (CamPaIGN) and “Parkinsonism: Incidence, 
Cognition and Non-motor heterogeneity in Cambridgeshire” (PICNICS) cohorts. Advantages of this 
study over some previously published studies include the long duration of follow-up, along with the 
fact that both cohorts consisted of community-based patients with newly diagnosed PD. 
 
Methods 
Patients 
The study population consisted of patients in the CamPaIGN and PICNICS cohorts – both community-
based incident PD cohorts (table 1)23. PD diagnosis was determined by the UK Parkinson’s Disease 
Society Brain Bank Criteria. The CamPaIGN cohort was recruited between 2000 and 2002 and subjects 
were followed up at 2 yearly intervals for up to 18 years.  The PICNICS cohort was recruited between 
2006 and 2013 and subjects have been followed up at 18 monthly intervals, so far for up to 11.4 years. 
Inclusion and exclusion criteria for these cohorts are summarised in supplementary table 1. The 
CamPaIGN and PICNICS studies were both approved by the Cambridgeshire Local Research Ethics 
Committee, and written informed consent was obtained from all subjects. 
 
Motor, cognitive and neuropsychiatric assessments were completed at each time point including the 
Unified Parkinson’s Disease Rating Scale (UPDRS) in the CamPaIGN cohort, Movement Disorders 
Society UPDRS (MDS-UPDRS) in the PICNICS cohort, Mini-Mental State Examination (MMSE), 
Hoehn and Yahr (HY) stage, levodopa equivalent dose, Beck Depression Inventory (BDI), National 
Adult Reading Test (NART) and Parkinson’s Disease Questionnaire-39 (PDQ-39). For the CamPaIGN 
cohort, estimated MDS-UPDRS scores were calculated as described previously24. Postural instability 
and gait disability (PIGD) and tremor scores were calculated for the CamPaIGN cohort as described 
here25. We adapted this method to allow calculation of similar motor phenotypes in the PICNICS cohort, 
using the mean value of the UPDRS-MDS scores for questions 2.10 (tremor history), 3.15 (postural 
tremor), 3.16 (kinetic tremor) and 3.17 (rest tremor) for tremor score, and questions 2.12 (walking and 
balance history), 2.13 (freezing history), 3.10 (gait examination) and 3.13 (posture examination) for 
PIGD score. GBA1 variants were identified through sequencing of the GBA1 gene targeted at exons 1 
to 11 in 250 patients, as described previously1. A further 127 patients underwent targeted screening 
using a Illumina Multi-Ethnic Genotyping Array (MEGA) ChIP for specific GBA1 variants 
(supplementary figure 1)26. 
 
Survival and regression analyses 
Subjects were grouped into non-carriers, and carriers of any GBA1 variant (GBA1-PD). The GBA1-PD 
group was further stratified into carriers of pathogenic mutations, and carriers of “non-pathogenic” 
variants, as indicated below. Hereafter, variants referred to as “pathogenic” are those associated with 
the development of GD in the homozygous or compound heterozygous state, and variants referred to as 
“non-pathogenic” are those that are not associated with the development of GD. All patients in whom 
sequencing had been undertaken were included in survival analyses, as well as additional patients in 
whom any GBA1 variant was detected on the MEGA ChIP array. Patients in which only MEGA ChIP 
screening was performed that were not found to carry a GBA1 variant were excluded, given the 
possibility that they carried an undetected GBA1 variant that had not been screened for. For subgroup 
analysis, , subjects that only had genotyping with the Mega ChIP array in which no GBA1 variant was 
identified, or in which a “non-pathogenic” variant was identified (n=6) were excluded, to ensure that 
there no patients with missed pathogenic mutations were included in the non-carrier or “non-
pathogenic” variant-carrier groups. 
 
Time to mortality, postural instability and dementia were selected as outcome measures, as these 
represent important clinical milestones in the progression of PD. Kaplan-Meier curves, and Cox 
Regression analyses controlling for potential confounders as detailed below, were used for comparison 
between the groups. Development of postural instability was defined as time to reach HY stage three 
(HY3) or PIGD score of two or more, and dementia was defined as a MMSE score of 24 or less, with 
fulfilment of Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria (functional 
impairment (as defined by Schwab and England score of 70% or less) with cognitive deficits in at least 
two domains and exclusion of other causes of cognitive dysfunction). The CamPaIGN and PICNICS 
cohort studies predated establishment of the Movement Disorder Society PD dementia criteria. Patients 
were only considered to have reached these outcomes if these criteria were fulfilled at all subsequent 
visits. 
 
Statistical analysis 
All statistical tests were performed on SPSS 25 (IBM) software. Independent samples T-tests were used 
to compare between non-carriers and carriers of all GBA1 variants. Levene’s test was first performed 
to ensure that equality of variance could be assumed. One-Way ANOVA tests were used for comparison 
between non-carriers and carriers of “non-pathogenic” or pathogenic GBA1 variants. Chi-squared tests 
were used to compare sex distribution. For survival analysis, log-rank values are reported, with 
comparison to the non-carrier group. 
 
 Non-
carriers 
All 
GBA1 
variants 
P-value GBA1 non-
pathogenic variant 
carriers 
Pathogenic 
GBA1 mutation 
carriers 
P-value 
 
Number 214 48 - 31 17 - 
Sex M:F 127:87 32:16 0.348 22:9 10:7 0.459 
Age at 
diagnosis 
69.2 (9.8) 68.3 
(8.9) 
0.569 68.7 (10.1) 67.5 (6.3) 0.785 
Years of 
follow-up 
6.9 (4.2) 6.1 (3.4) 0.255 6.8 (3.6) 6.2 (2.8) 0.791 
Years in 
education 
11.9 (3.1) 11.3 
(2.5) 
0.253 11.3 (2.5) 11.5 (2.7) 0.510 
Total 
UPDRS at 
baseline 
51.8 (19.6) 54.2 
(16.8) 
0.431 56.2 (18.3) 50.0 (15.2) 0.452 
Motor 
UPDRS at 
baseline 
31.6 (12.5) 35.1(12.0
) 
0.072 35.7 (12.1) 35.1 (13.2) 0.168 
Hoehn & 
Yahr at 
baseline 
1.7 (0.7) 2.0 (0.8) 0.02 2.0 (0.74) 2.0 (0.8) 0.067 
PIGD 
score at 
baseline 
0.75 (0.55) 0.85 
(0.47) 
0.225 0.86 (0.52) 0.79 (0.34) 0.563 
Tremor 
score at 
baseline 
0.59 0.41) 0.61 
(0.41) 
0.744 0.75 (0.42) 0.51 (0.35) 0.119 
Baseline 
levodopa 
equivalent 
dose 
185.9 mg 
(238.7) 
204.4 mg 
(241.1) 
0.594 166.1 mg (214.1) 274.1 mg 
(277.0) 
0.290 
MMSE at 
baseline 
28.5 (1.4) 28.2 
(1.9) 
0.274 27.9 (2.1) 28.6 (1.4) 0.150 
BDI at 
baseline 
7.3 (5.3) 6.8 (5.0) 0.629 7.8 (5.6) 4.9 (2.9) 0.180 
NART at 
baseline 
116.1 
(61.9) 
111.3 
(11.3) 
0.609 109.7 (10.7) 113.2 (12.0) 0.873 
PDQ-39 at 
baseline 
24.7 (19.8) 26.4 
(19.8) 
0.602 32.5 (22.3) 17.5 (9.2) 0.057 
Table 1 – Patient demographics. P-values are shown for comparison between non-carriers and all 
variant-carriers as determined by independent samples T-tests and Chi-squared tests, and for 
comparison between non-carriers, “non-pathogenic” variant-carriers, and pathogenic variant carriers, 
as determined by One-Way ANOVA and Chi squared tests. Standard deviations shown in brackets. 
Abbreviations: BDI = Beck Depression Inventory; F = female; M = male; MMSE = mini mental state 
examination; NART = National Adult Reading Test; PDQ-39 = Parkinson’s disease questionnaire 39; 
PIGD = postural instability and gait disability; UPDRS = Unified Parkinson’s Disease Rating Scale. 
 
Results 
 
Incidence and spectrum of GBA1 abnormalities 
GBA1 variants were present in 36 out of the 250 patients in which sequencing was performed (14.4%). 
Pathogenic mutations were present in 11 of these patients (4.4 %), which included N370S (n=3), L444P 
(n=3), R463C (n=1), G10S (n=1), N426K (n=1), R48W (n=1) and R257Q (n=1). Isolated “non-
pathogenic” variants were present in 25 of these patients (10.0 %). These included c.762 18T>A (n=8), 
E326K (n=7), T369M (n=7), E388K (n=1), L119L (n=1) and c.589 86A>G) (n=1). The carrier of the 
pathogenic R48W variant carried a concomitant E326K variant, and the carrier of the pathogenic 
N426K variant carried a concomitant c.762 18T>A variant. These were both included in the pathogenic 
variant group for subgroup analyses. Variants were identified in 12 of the 127 patients (9.4%) in which 
MEGA ChIP analysis was performed. These included the pathogenic N370S (n=4), R463C (n=1) and 
G10S (n=1) variants, and the “non-pathogenic” T369M (n=3), E326K (n=2) and E388K (n=1) variants.  
 
After excluding those patients in which only MEGA ChIP genotyping was performed that were not 
identified to carry a GBA1 variant, these combined cohorts contained 214 non-carriers and 48 carriers 
of GBA1 variants. Mean follow-up times were 8.0 years (maximum 18.0 years) for the CamPaIGN 
cohort (n=115) and 5.8 years (maximum 11.4 years) for the PICNICS cohort (n=147). 
 
Cognitive decline and risk of dementia 
Baseline cognitive function did not differ between variant carriers and non-carriers, with no significant 
differences in MMSE scores at initial assessment (table 1). Carriers of any GBA1 variant had an 
increased risk of progression to dementia compared to non-carriers (table 2 and figure 1). Cox 
regression analysis controlling for age at diagnosis, sex and baseline MMSE score revealed that 
development of dementia was significantly more likely in carriers of any GBA1 variant, compared to 
non-carriers, with a hazard ratio (HR) of 2.1 (95 % confidence interval (CI) 1.2-3.9, p=0.013). At the 
10 year time point, fewer than half of the variant carriers remained dementia-free, in comparison to 68.4 
% of non-carriers. At 15 years, 64.2 % of surviving non-carriers remained dementia-free. All patients 
in the GBA1 carrier group had developed dementia or died prior to the 15 year time point. The estimated 
mean time to dementia was approximately five years earlier in variant carriers, compared to non-carriers 
(table 2). 
 
Sub-classification of the variant-carrier group into those with pathogenic mutations and those with 
“non-pathogenic” variants revealed a significantly increased risk of progression to dementia in carriers 
of pathogenic variants, with a HR of 3.6 (95 % CI 1.5-8.3, p=0.003). In carriers of “non-pathogenic” 
variants there was a non-significant trend towards increased risk of dementia (HR 1.8 (95% CI 0.9-3.8, 
p=0.11). 
 
 Non-carriers All GBA1 
variants 
Non-pathogenic 
variants  
Pathogenic 
mutations 
Number 214 48 25 17 
Estimated mean time 
to dementia (years) 
13.7 (12.6-14.7) 8.6 (7.2-10.0) 8.3 (6.4-10.2) 8.3 (6.2-10.3) 
Estimated median 
time to dementia 
(years) 
* 8.5 (6.9-10.1) 8.3 (5.4-11.3) 8.5 (4.1-12.9) 
5 year survival 
without dementia 
(%) 
85.3 (SE 2.7) 80.2 (SE 6.3) 82.3 (SE 8.0) 74.0 (SE 11.2) 
10 year survival 
without dementia 
(%) 
68.4 (SE 4.3) 45.7 (SE 9.8) 43.2 (SE 12.5) 43.2 (SE 16.0) 
15 year survival 
without dementia 
(%) 
64.2 (SE 5.8) 0 0 0 
Log-rank p-value - 0.013 0.014 0.109 
Hazard ratio - 2.1 (1.2-3.9; 
p=0.013) 
1.8 (0.9-3.8; 
p=0.110) 
3.6 (1.6-8.3; 
p=0.003) 
Table 2 – Time to dementia. Long-term follow-up data for progression to dementia in PD patients 
without GBA1 variants compared to those carrying any GBA1 variant, a pathogenic GBA1 mutation, or 
a GBA1 “non-pathogenic” variant. HR determined by Cox regression analysis controlling for age at 
diagnosis, sex and baseline MMSE score. 95 % CI for HR and estimated mean and median shown in 
brackets. Log-rank p-values shown for comparison between the GBA1 groups and the non-carrier group. 
Abbreviations: SE = standard error of the mean. *fewer than half reached outcome. 
 
Motor progression 
The baseline HY stage was lower in non-carriers compared to carriers (table 1), though there were no 
significant differences between the subgroups. There were no differences in baseline UPDRS motor 
score, PIGD score or levodopa equivalent dose between any of the groups. The risk of progression to 
postural instability was increased in the GBA1-PD group in comparison to non-carrier group (table 3 
and figure 2). At five years from diagnosis, 67.5 % of the GBA1-PD group had reached HY3, compared 
to 43 % of non-carriers. After controlling for potential confounders (age at diagnosis, sex, baseline HY 
score, baseline UPDRS motor score, and baseline PIGD score) the risk of progression to HY3 was 
significantly greater in both carriers of “non-pathogenic” variants and pathogenic mutations, with a HR 
of 1.7 (95 % CI 1.0-2.9, p=0.035) and 1.9 (95 % CI 1.0-3.4, p=0.036) respectively (figure 2 and table 
3). 
 
 Non-carriers All GBA1 
variants 
Non-pathogenic 
variants  
Pathogenic 
mutations 
Number 213 48 25 17 
Estimated mean time 
to HY3 (years) 
6.8 (5.9-7.6) 4.7 (3.4-5.9) 4.6 (3.0-6.3) 4.4 (3.0-5.9) 
Estimated median 
time to HY3 (years) 
6.0 (4.6-7.4) 3.0 (2.5-3.5) 2.8 (2.5-3.1) 4.4 (2.6-6.2) 
5 year survival 
without postural 
instability (%) 
57.0 (SE 3.6) 32.5 (SE 7.3) 32.0 (SE 10.0) 32.4(SE 11.8) 
10 year survival 
without postural 
instability (%) 
28.7 (SE 4.1) 9.6 (SE 5.9) 10.7 (SE 7.0) 0 
15 year survival 
without postural 
instability (%) 
7.7 (SE 3.9) 9.6 (SE 5.9) 10.7 (SE 7.0) 0 
Log-rank p-value - 0.013 0.074 0.095 
Hazard ratio - 1.7 (1.2-2.6; 
p=0.006) 
1.7 (1.0-2.9; 
p=0.035) 
1.9 (1.0-3.4; 
p=0.036) 
Table 3 – Time to HY3. Long-term follow-up data for progression to postural instability in PD patients 
without GBA1 variants compared to those carrying any GBA1 variant, a pathogenic GBA1 mutation, or 
a GBA1 “non-pathogenic” variant. HR determined by Cox regression analysis controlling for age at 
diagnosis, sex, baseline HY score, baseline UPDRS motor score, and baseline PIGD score. 95 % CI for 
HR and estimated mean and median shown in brackets. Log-rank p-values shown for comparison 
between the GBA1 groups and the non-carrier group. Abbreviations: HY3 = Hoehn and Yahr stage 
three; SE = standard error of the mean. 
 
Time to PIGD score of two or more was also determined as a measure of motor progression. Pathogenic 
variants were associated with an increased risk of progression to PIGD score of two or more, with a HR 
of 2.8 (95% CI 1.4-5.7, p=0.005). There was no significant increased risk of progression to PIGD score 
of two or more in carriers of “non-pathogenic” variants (table 4). 
 
 Non-carriers All GBA1 
variants 
Non-pathogenic 
variants  
Pathogenic 
mutations 
Number 214 48 25 17 
Estimated mean time 
to PIGD≥2 (years) 
7.7 (7.2-8.3) 6.8 (5.6-7.9) 6.9 (5.3-8.5) 5.7 (4.4-7.0) 
Estimated median 
time to PIGD≥2 
(years) 
8.6 (7.4-9.9) 6.0 (5.1-7.0) 6.0 (5.1-7.0) 4.9 (3.1-6.6) 
5 year survival to 
PIGD≥2 (%) 
76.1 (SE 3.2) 62.6 (SE 8.1) 71.5 (SE 9.9) 48.8 (SE 13.9) 
10 year survival to 
PIGD≥2 (%) 
40.9 (SE 5.6) 37.9 (SE 8.8) 39.0 (SE 12.0) 30.5 (SE 13.5) 
Log-rank p-value - 0.094 0.335 0.066 
Hazard ratio - 1.9 (1.1-3.2; 
p=0.015) 
1.6 (0.8-3.1; 
p=0.178) 
2.8 (1.4-5.7; 
p=0.005) 
Table 4 – Time to PIGD score of two or more. Long-term follow-up data for progression to postural 
instability in PD patients without GBA1 variants compared to those carrying any GBA1 variant, a 
pathogenic GBA1 mutation, or a GBA1 “non-pathogenic” variant. HR determined by Cox regression 
analysis controlling for age at diagnosis, sex, baseline HY score, baseline UPDRS motor score, and 
baseline PIGD score. 95 % CI for HR and estimated mean and median shown in brackets. Log-rank p-
values shown for comparison between the GBA1 groups and the non-carrier group. Abbreviations: HY3 
= Hoehn and Yahr stage three; PIGD = postural instability and gait difficulty score; SE = standard error 
of the mean. 
 
Mortality 
Mean time to mortality was approximately one year earlier in carriers of any GBA1 variant compared 
to non-carriers (table 5 and figure 3). At 15 years from diagnosis, only 5.3% of GBA1 variant carriers 
were surviving, compared to 20.1% of non-carriers. When controlling for age and sex, the risk of 
mortality was increased in carriers of pathogenic mutations in comparison to non-carriers with a HR of 
2.1 (95 % CI 1.0 to 4.1, p=0.043), but not in those carrying “non-pathogenic” variants (table 5). 
 
To explore whether the increase in mortality associated with pathogenic GBA1 variants was attributable 
to the development of dementia, the dementia outcome was added into the Cox regression model, along 
with age and sex. The increased risk of mortality associated with carrying any GBA1 variant persisted 
after controlling for dementia status (HR 2.0 (95 % CI 1.0-4.1, p=0.046)), suggesting that the 
relationship was independent of the development of dementia. Causes of death in each group are shown 
in supplementary table 2. 
 
 Non-carriers All GBA1 variants Non-pathogenic 
variants  
Pathogenic 
mutations 
Number 214 48 25 17 
Estimated 
mean time to 
death (years) 
10.6 (10.0-11.3) 9.4 (8.4-10.5) 10.0 (8.7-11.3) 9.5 (7.8-11.3) 
Estimated 
median time to 
death (years) 
10.0 (9.3-10.7) 9.4 (8.3-10.6) 10.0 (8.9-11.1) 8.5 (7.7-9.3) 
5 year survival 
(%) 
89.2 (SE 2.2) 93.4 (SE 3.7) 96.0 (SE 3.9) 100.0 
10 year 
survival (%) 
49.6 (SE 3.9) 39.8 (SE 8.8) 49.7 (SE 11.6) 29.8 (SE 14.1) 
15 year 
survival (%) 
20.1 (SE 3.9) 5.3 (SE 5.0) 7.8 (SE 7.3) 0 
Log-rank p-
value 
- 0.169 0.639 0.275 
Hazard ratio - 1.5 (1.0-2.3; 
p=0.061) 
1.2 (0.7-2.0; 
p=0.567) 
2.1 (1.0-4.1; 
p=0.043) 
Table 5 – Time to mortality. Long-term follow-up data for progression to time to mortality in PD 
patients without GBA1 variants compared to those carrying any GBA1 variant, a pathogenic GBA1 
mutation, or a GBA1 “non-pathogenic” variant. HR determined by Cox regression analysis controlling 
for age at diagnosis and sex. 95 % CI for HR and estimated mean and median shown in brackets. Log-
rank p-values shown for comparison between the GBA1 groups and the non-carrier group. 
Abbreviations: SE = standard error of the mean. 
 
Discussion 
 
In this study, we have described the clinical course of incident GBA1-PD for up to 18 years from the 
time of diagnosis, which is a longer follow-up period than any previous study. We have demonstrated 
that GBA1 variants confer an increased risk of dementia, faster motor progression, and mortality in PD, 
in keeping with previous reports. Importantly, in addition to pathogenic GBA1 mutations, variants 
generally considered to be “non-pathogenic”, were found to adversely affect disease course in GBA1-
PD. 
 
By studying patients with incident PD for up to 18 years, this study has uniquely described the natural 
history of GBA1-PD. Most prior longitudinal studies of GBA1-PD have employed prevalent cohorts in 
which variation in disease duration may confound the results, and many other studies have used clinic-
based cohorts which may be disproportionately represented by atypical or severe cases.  The two cohorts 
analysed in this study were community-based and thus more representative of the general PD 
population. Another strength of this study was the inclusion of patients with GBA1 variants that do not 
cause GD, which occur at increased incidence in PD. These variants were termed “non-pathogenic” to 
differentiate them from variants that cause GD, though taking into account results from this and 
previous studies, they should not be considered to be non-deleterious. 
 
Of the patients that had undergone genetic sequencing, 14% carried a GBA1 variant, with 4.4% carrying 
a pathogenic mutation2-4 27 previously associated with GD. The frequency of pathogenic mutations was 
similar to that seen in previous studies. The prevalence of any GBA1 variant was higher than that seen 
in other studies, probably due to the fact that we included non-coding variants such as c.762 18T>A, 
which has been reported as a potential risk factor for PD, though its importance is not clear28. The most 
common variants were c.762 18T>A, E326K, and T369M which accounted for almost two thirds of all 
variants. Carriers of these variants are a particularly interesting group to study, as their clinical 
significance is much less clear than that of so called “pathogenic” GBA1 mutations. 
 
We found that GBA1 variants were generally associated with a more aggressive disease course. 
Diagnosis of dementia and development of postural instability were chosen as outcome measures, since 
these represent important milestones in the clinical progression of PD29. Consistent with previous 
studies, carriers of pathogenic mutations had an increased risk of reaching both of these milestones. 
Carriers of any GBA1 variant had a projected mean time to dementia that was approximately five years 
earlier than in non-carriers, whilst the estimated mean time to development of postural instability was 
approximately two years earlier than that seen in non-carriers. Carriers of pathogenic mutations had a 
3.6-fold greater risk of development of dementia than in non-carriers, and a 1.9-fold greater risk of 
progression to HY3. Importantly, carriers of variants not associated with GD conveyed a similar risk of 
development of postural instability in comparison to non-carriers, with a trend towards greater risk of 
dementia. These variants have previously been reported to have little effect on clinical course in PD14, 
though it is possible that such effects would be missed due to short follow-up times, and heterogeneous 
populations. Carriers of the common E326K variant have been shown to have an increased risk of 
dementia and motor progression in comparison to non-carriers, in one US-based study20. However, in a 
large meta-analysis of GBA1 variants in PD, there was no association between development of PD and 
the E326K variant4. This study population was enriched for individuals from Jewish, Portuguese, and 
Asian populations, in which the E326K accounts for a lower proportion of GBA1 variants than in other 
populations, which may account for the lack of association in this analysis3 30.  
 
We also found a significantly increased risk of mortality over the study period in carriers of pathogenic 
GBA1 variants, in which the risk of death was approximately two-fold greater than that in non-carriers, 
with a mean time to mortality approximately one year earlier. This observation was not attributable to 
the increased incidence of dementia in GBA1 variant carriers, since the effect persisted after controlling 
for dementia status. Other factors (such as immobility, adverse drug effects, and non-motor features) 
may contribute to the observed increase in mortality in GBA1-PD. “Non-pathogenic” variants were not 
associated with an increased risk of mortality, though the time to mortality was non-significantly 
reduced in this group. The impact of GBA1 variants on PD progression may lie on a spectrum, with 
pathogenic mutations conveying a greater biological effect than “non-pathogenic” variants. As such our 
study may have been underpowered to detect a small reduction in time to mortality associated with 
“non-pathogenic” variants, and it would be interesting to explore this in a larger cohort. 
 
Age of disease onset has previously been reported to be reduced in PD associated with GBA1 
mutations10 13 27 31. In this study, age of onset did not differ based on GBA1 status. The mean age of onset 
in both carriers of pathogenic mutations and carriers of “non-pathogenic” variants in GBA1 was 
approximately two years earlier than in non-carriers, and it may be that this study was underpowered to 
detect such a difference in age at onset. 
 
The observation that “non-pathogenic” GBA1 variants adversely affect the prognosis of PD patients is 
important. This significantly increases the proportion of PD patients in which GBA1 abnormalities play 
a potentially pathogenic role, in comparison to considering GD-causative mutations as the only variants 
that alter PD course. Given that GBA1 mutations are associated with the specific pathology of lysosome-
autophagy system dysfunction32, it is possible that the optimal treatment approach in this group of 
patients will involve drugs that are able to restore activity of this system. As such treatments emerge, it 
may become important to screen PD patients for variants in the GBA1 gene, so that precision medicine 
can be applied, and our data suggests that it will be important to screen for a much broader range of 
variants than those previously identified as “pathogenic”. 
 
The “pathogenic” mutations associated with GD result in significant reduction in glucocerebrosidase 
enzyme activity, which underlies its clinical manifestations5 33. However, polymorphisms such as 
E326K result in a relatively minimal reduction in enzyme activity22, and the fact that these predispose 
to PD without being associated with GD, supports the concept that the pathogenic mechanisms of 
GBA1-PD are distinct from those of GD. This means that putative treatments for GBA1-PD may need 
to correct glucocerebrosidase folding and structure, or restore activity of dysfunctional pathways (such 
as the lysosome-autophagy system), rather than simply restoring glucocerebrosidase enzyme activity. 
 
We acknowledge that there are a number of limitations with our study. While we have controlled for 
relevant potential confounders in our survival analyses, data regarding prodromal features of PD that 
may influence prognosis (e.g. REM sleep-behaviour disorder) were not available. We have reported on 
the time from diagnosis, rather than time from symptom onset, to the development of clinical 
milestones, which may not truly reflect disease duration. However, the time of symptom onset is 
difficult to determine accurately, since many prodromal features may not be attributed to PD, which 
would potentially introduce bias. 
 
These cohorts predated the development of the MDS criteria for PD dementia. Cognitive status was 
measured in these cohorts with MMSE, though other cognitive examinations are now favoured. In order 
to maximise the accuracy of dementia diagnosis in these cohorts we employed strict criteria that reflect 
the MDS criteria for PD dementia, including a requirement for irreversible deficits in multiple cognitive 
domains accompanied by functional impairment. Though we included baseline MMSE as a covariate 
in our Cox regression model for time to dementia, it is not known how many patients had mild cognitive 
impairment at baseline, which may be expected to influence prognosis. Because assessments were 
performed every two years for the CamPaIGN cohort, and every 18 months for the PICNICS cohort, it 
was not possible to determine the exact time of the onset of dementia or progression to HY3 or PIGD 
score of two or more, which was determined as the mid-point between the assessment at which the 
patient had reached the outcome measure, and the prior assessment. 
 
Another limitation of our study is the relatively limited sample size. We have attempted to address this 
by using two homogeneous incident cohorts from the same population base but separated in time23. 
However, 115 patients were excluded from survival analyses as they had only undergone limited genetic 
screening, meaning that it was possible that they harboured unidentified, potentially clinically 
significant GBA1 variants. The sequencing of GBA1 conferred major benefits in this study, as a more 
comprehensive method for identifying both presence of absence of GBA1 variants. Whilst we 
acknowledge that complete sequencing reads could not be achieved in all patients (as previously 
described in Winder-Rhodes et al 2013), we feel that the use of sequencing data allowed us to assign 
GBA1 variant carrier status with maximum possible accuracy. Further strengths of this study are the 
long duration of follow-up of up to 18 years, and the fact that our cohorts consisted of incident PD 
patients recruited from the community, allowing follow up from diagnosis to the development of key 
clinical milestones in a representative population. As such we have presented the first long-term data 
on the effect of GBA1 variants on mortality in an incident PD population, and detected significant 
differences in the natural history of PD associated with “non-pathogenic” GBA1 variants, which may 
have been missed in previous studies, probably due to their limited follow-up durations. 
 In conclusion, long-term follow-up of the CamPaIGN and PICNICS cohorts confirms that GBA1 
mutations adversely affect clinical course. Importantly, carriers of GBA1 variants that are often 
considered to be “non-pathogenic” had a significantly worse clinical course than non-carriers. GBA1 
variants therefore contribute to the pathogenesis and clinical features of more than 10 % of PD patients, 
making them a particularly important genetic sub-group. Since GBA1 abnormalities appear to be 
associated with specific pathogenic mechanisms, it may be that the optimal disease-modifying approach 
differs in this group than in the wider PD population, with important implications for future clinical 
trials. 
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Figure Legends 
 
 
Figure 1 - Effect of GBA1 variants on development of dementia in PD. A) Survival analysis for time 
to dementia in carriers of any GBA1 variant compared to non-carriers. B) Subgroup survival analysis 
for time to dementia in carriers of pathogenic GBA1 mutations, “non-pathogenic” variants, and non-
carriers. Statistical significance as determined by log-rank tests indicated by asterixes. 
 
Figure 2 - Effect of GBA1 variants on development of postural instability in PD. A) and C) Survival 
analysis for time to HY3 and PIGD score of two or more respectively, in carriers of any GBA1 variant 
compared to non-carriers. B) and D) Subgroup survival analysis for time to HY3 and PIGD score of 
two or more respectively,  in carriers of pathogenic GBA1 mutations, “non-pathogenic” variants, and 
non-carriers. Statistical significance as determined by log-rank tests indicated by asterixes. 
 Figure 3 - Effect of GBA1 variants on time to death in PD. A) Survival analysis for time to death in 
carriers of any GBA1 variant compared to non-carriers. B) Subgroup survival analysis for time to death 
in carriers of pathogenic GBA1 mutations, “non-pathogenic” variants, and non-carriers. 
  
Supplementary Material 
 
 
 CamPaIGN PICNICS 
Inclusion 
criteria 
 New cases with Parkinsonism 
diagnosed December 1 2000 to 
December 31 2002 
 Recruited from community 
(Cambridgeshire) 
 Diagnosis validated by a movement 
disorder specialist using UKPD Brain 
Bank criteria at baseline 
assessment (with re-validation at 
3.5 years) 
 New cases of Parkinsons’s disease 
diagnosed between November 1 2006 
and May 8 2013 
  Recruitment from community, 
Cambridgeshire 
 UKPD BB criteria at baseline 
Exclusion 
criteria 
 MMSE of < 24 at baseline 
 Failure to meet UKPD Brain Bank 
criteria at subsequent follow-up 
 Diagnosis other than idiopathic PD 
 Dementia at baseline 
 Failure to meet UKPD Brain Bank 
criteria at subsequent follow-up 
 Diagnosis other than idiopathic PD 
Supplementary table 1. Inclusion and exclusion criteria for CamPaIGN and PICNICS cohorts. 
  
 Non-carriers GBA1 non-pathogenic 
variant carriers 
Pathogenic GBA1 
mutation carriers 
Infection 41 (32.5%) 
- Respiratory n=36 
- UTI n=4 
- UTI + pneumonia n=1 
5 (26.3%) 
- Respiratory n=5 
2 (22.2%) 
- Respiratory n=1 
- Infected fracture n=1 
Parkinson’s 
disease 
14 (11.1%) - 1 (11.1%) 
Cardiovascular 8 (6.3%) 
- Congestive cardiac failure n=3 
- Myocardial / pericardial fibrosis 
n=2 
- HOCM n=1 
- Cardiac arrest n=1 
- Ruptured AAA n=1 
2 (10.5%) 
- Myocardial infarction 
n=2 
- 
Malignancy 5 (4.0%) 
- Prostate n=1 
- Bowel n=1 
- Renal sarcoma n=1 
- Lung n=1 
- Not-specified n=1 
- - 
Old age / frailty 4 (3.2%) - - 
Stroke 2 (1.6%) 1 (5.3%) - 
Gastrointestinal 2 (1.6%) 
- Stercoral bowel perforation n=1 
- Gastrointestinal haemorrhage 
n=1 
- 1 (11.1%) 
- Sigmoid volvulus n=1 
Other 5 (4.0%) 
- COPD n=2 
- Liver failure n=1 
- Subdural haematoma n=1 
- Suicide n=1 
- - 
Unknown 45 (35.7%) 11 (57.9%) 5 (55.6%) 
Supplementary table 2. Causes of death for non-carriers and carriers of “non-pathogenic” and 
pathogenic GBA1 variants with Parkinson’s disease. Causes of death were determined through 
analysis of medical certificates of the cause of death where accessible. Abbreviations: AAA = 
Abdominal aortic aneurysm; COPD = Chronic obstructive pulmonary disease; HOCM = Hypertrophic 
obstructive cardiomyopathy; UTI = Urinary tract infection. 
  
 Non-
carriers 
All GBA1 
variants 
P-value GBA1 non-
pathogenic variant 
carriers 
Pathogenic 
GBA1 mutation 
carriers 
P-value 
 
Years from 
diagnosis 
to baseline 
visit (SD) 
0.23 (0.33) 0.28 
(0.33) 
0.344 0.31 (0.35) 0.24 (0.28) 0.534 
Supplementary table 3. Time from diagnosis to first assessment for patients in CamPaIGN and 
PICNICS cohorts. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1. Genetic analysis in CampaIGN and PICNICS cohorts. 
 
 
CamPaIGN cohort 
n=142 
PICNICS cohort 
n=280 
Genetic screening 
n=130 
Genetic screening 
n=247 
Excluded: 
- Revised diagnosis (not PD) n=1 
- No genetic analysis available n=11 
Excluded: 
- No genetic analysis available n=33 
Sequencing 
n=114 
MEGA ChIP 
n=16 
Sequencing 
n=136 
MEGA ChIP 
n=111 
-Non-carrier n=93 
-Non-pathogenic 
variant n=15 
-Pathogenic variant 
n=6 
-Non-pathogenic 
variant n=1 
-Pathogenic variant 
n=0 
-Non-carrier n=121 
-Non-pathogenic 
variant n=10 
-Pathogenic variant 
n=5 
-Non-pathogenic 
variant n=5 
-Pathogenic variant 
n=6 
